Share this article and save a life!
5 million lupus patients just got their first real hope in decades.
Johnson & Johnson just announced something extraordinary today: nipocalimab, the first FcRn blocker to show positive results in treating systemic lupus erythematosus (SLE).
This is bigger than just another drug approval.
Lupus has been one of medicine’s most frustrating puzzles. Patients, mostly women between 15-45, face a brutal reality:
• Unpredictable flares that attack multiple organs
• Current treatments that barely control symptoms
• Immunosuppressants with devastating side effects
• Average diagnosis time: 6 years of suffering
Nipocalimab works differently. It blocks the FcRn receptor, essentially teaching the immune system to stop recycling the harmful antibodies that attack healthy tissue.
Think of it like this: instead of suppressing the entire immune system with a sledgehammer, we’re using a scalpel to remove just the problematic antibodies.
The Phase 2b data shows what patients have been waiting for: actual disease activity reduction, not just symptom management.
J&J is moving straight to Phase 3 trials. For context, this is the FIRST positive data ever for this drug class in lupus.
Here’s what this means for healthcare:
🔬 Precision medicine is finally reaching autoimmune diseases
📊 3-5 million patients globally could see transformed outcomes
💰 Reduced long-term costs from organ damage prevention
🏥 Health systems need to prepare for a new treatment paradigm
The real victory? This validates an entirely new approach to autoimmune disease. If FcRn blockers work for lupus, what about the 80+ other autoimmune conditions?
We’re not just treating symptoms anymore. We’re rewriting the immune system’s code.
For every lupus patient who’s been told “there’s nothing more we can do,” that just changed today.
♻️ Repost if autoimmune breakthroughs deserve more attention
👉 Follow me, Jonathan Govette, for real-time updates on healthcare technology and business news. LinkedIn Profile: https://www.linkedin.com/in/jonathangovette/
Share this article and save a life!
Author:
CEO/Co-Founder @ Oatmeal Health | AI Lung Cancer Screening | Almost Became a Doctor | Engineer | Follow to Share What I’ve Learned Along the Way
I help patients get the care they need earlier, preventing late-stage cancer.
That’s been the throughline across three companies and almost 20 years in healthcare. At ReferralMD, we fixed broken referral networks so patients didn’t fall through the cracks. At Oatmeal Health, it’s lung cancer: building the diagnostic and screening infrastructure so the 85% of cases caught too late get caught early instead.
Today as CEO of Oatmeal Health, I lead a team embedding AI into radiology workflows to turn routine lung CT scans into reimbursable cancer risk assessments. We partner with FQHCs to reach underserved communities, and with health systems and payers to make early detection economically sustainable. Think HeartFlow or Cleerly, but for lungs.
Between companies, I advised at Techstars and Plug and Play, mentoring founders building in digital health. That experience shaped how I think about what separates companies that ship from companies that stall: distribution, reimbursement, and clinical trust, not just technology.
I’m a CancerX alumnus, a 3x healthcare founder, and someone who believes the biggest problems in cancer aren’t scientific. They’re operational.
We’re hiring mission-driven builders at Oatmeal Health. If you want to work on something that matters, reach out.
When I’m not working, I’m traveling, mentoring, and keeping up with one very energetic husky. 🐾
Substack – The Oatmeal Bite:
Millions of patients get less care because of who they are, where they live, or how they look. I’m fighting to change that. CEO @OatmealHealth, a startup built for the underserved. The Oatmeal Bite: intel for clinicians, investors, and advocates.
Jonathan Govette
CEO of Oatmeal Health
Substack:
https://oatmealhealthjonathangovette.substack.com/
